Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression


Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.

Related Videos
Related Content